Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
301 studies found for:    nash
Show Display Options
RSS Create an RSS feed from your search for:
nash
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
Intervention:
2 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
3 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
4 Recruiting BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Condition: Non-Alcoholic Steatohepatitis
Interventions: Device: Suspected NASH BreathID test with 13C-Octanoate;   Device: Suspected NASH Breath test with 13C Methacetin
5 Completed
Has Results
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo
6 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Drug: Elafibranor;   Drug: Placebo
7 Recruiting Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease
Conditions: Healthy;   NAFLD (Non-Alcoholic Fatty Liver Disease);   NASH (Non-Alcoholic Steatohepatitis)
Interventions: Other: NAFLD/NASH - Placebo;   Dietary Supplement: NAFLD/NASH - Vitamin E
8 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
9 Recruiting A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MSDC-0602K;   Drug: Placebo capsules
10 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: LMB763;   Drug: Placebo
11 Completed Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
12 Recruiting Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH
Conditions: Obesity;   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease
Intervention: Behavioral: Comprehensive Lifestyle Intervention
13 Recruiting Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conditions: Non-alcoholic Steatohepatitis;   Fibrosis;   Liver Diseases
Interventions: Drug: Emricasan (5 mg);   Drug: Emricasan (50 mg);   Drug: Placebo
14 Completed Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
15 Recruiting A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
Intervention:
16 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
17 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
18 Recruiting Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
Condition: NASH Related Decompensated Cirrhosis
Interventions: Drug: Fecal Microbiota Transplantation;   Drug: Standard Treatment;   Other: Weight Reduction
19 Recruiting Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Weight Loss;   Non-alcoholic Steatohepatitis (NASH)
Interventions: Behavioral: Lifestyle modification;   Drug: Liraglutide
20 Active, not recruiting Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years